Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 15/20 | 0.57 |
| ▸ | VCP | P55072 | 4/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722329 | 1.00 | FBP1 (0.57) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL29007465 | 1.00 | FBP1 (0.57) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| Acetic Acid SCHEMBL29750417 | 0.88 | VCP (0.46) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL3696051 | 0.84 | FBP1 (0.53) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL3696050 | 0.84 | FBP1 (0.53) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL15985663 | 0.84 | FBP1 (0.53) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL2285892 | 0.81 | FBP1 (0.67) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL2285894 | 0.81 | FBP1 (0.67) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL793784 | 0.80 | VCP (0.72) | FBP1VCPMITFALDH1A1HSP90AA1 | |
| SCHEMBL30592059 | 0.80 | VCP (0.72) | FBP1VCPMITFALDH1A1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116199582-A | Preparation method of 3',4',5 '-trifluoro-2-nitro-1, 1' -biphenyl | 南通泰禾化工股份有限公司 | 2023-06-02 | — | — | CN | claimed |
| WO-2025054260-A1 | INHIBITORS OF MEK KINASE | KINNATE BIOPHARMA INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4267568-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116199582-A | Preparation method of 3',4',5 '-trifluoro-2-nitro-1, 1' -biphenyl | 南通泰禾化工股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2022144274-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-07-07 | — | — | WO | disclosed |
| US-8853455-B2 | Process for preparing substituted 2-nitrobiphenyls | BASF SE (DE) | 2014-10-07 | — | — | US | disclosed |
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2406210-A1 | PROCESS FOR PREPARING SUBSTITUTED 2-NITROBIPHENYLS | BASF SE (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319665-A1 | Process for Preparing Substituted 2-Nitrobiphenyls | BASF SE (DE) | 2011-12-29 | — | — | US | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| WO-2010102980-A1 | PROCESS FOR PREPARING SUBSTITUTED 2-NITROBIPHENYLS | BASF SE (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319665-A1 | Process for Preparing Substituted 2-Nitrobiphenyls | CYP2J2, LTC4S, CYP1A2 | FBP1 4024/4885VCP 706/4885MITF 4174/4885 |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | FBP1 3778/4885VCP 2532/4885MITF 4315/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | FBP1 3778/4885VCP 2532/4885MITF 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.